Prasad Raju 4

What Happened

• Prasad Raju, Chief Financial Officer of CRISPR Therapeutics (CRSP), had 16,875 restricted stock units (RSUs) convert to common shares on March 14, 2026 (10,000 from a 2023 grant and 6,875 from a 2025 grant). On March 16, 2026 he sold 9,869 of those shares in open-market transactions at $48.26 per share for total proceeds of $476,277. He also transferred (gifted) 750 shares on March 16. The sale of 9,869 shares was reported as the number required to be sold to cover tax withholding obligations under the company’s RSU Settlement Policy (not a discretionary trade).

Key Details

• Transaction dates and prices:
  • 2026-03-14: 16,875 RSUs vested / converted to common shares (10,000 + 6,875).
  • 2026-03-16: Open-market sales — 5,848 shares and 4,021 shares at $48.26 each (total sold 9,869; proceeds $282,224 + $194,053 = $476,277).
  • 2026-03-16: Gift of 750 shares (no consideration received).
• Net shares retained from this vesting event: 16,875 − 9,869 − 750 = 6,256 shares (these remaining shares and some others remain subject to underwriter lock-up provisions).
• Notable footnotes:
  • Sales to cover tax withholding were mandated by company RSU Settlement Policy (F3).
  • Portions of the shares remain subject to a lock-up agreement with underwriters of the issuer’s convertible note offering (F1, F4).
  • The RSU awards and their vesting schedules are described in the filing (grants dated 3/14/2023 and 3/14/2025; quarterly vesting).
• Filing: Form 4 filed 2026-03-17 reporting the March 14 (vesting) and March 16 (sales/gift) transactions.

Context

• The March 14 entries reflect the vesting/conversion of RSUs (derivative exercise/conversion). The subsequent open-market sales were to satisfy tax withholding obligations (company-mandated), which is common and not an indication of discretionary insider selling.
• The 750-share transfer was a bona fide gift permitted under the lock-up; gifts do not necessarily reflect trading intent.
• Purchases (bullish signals) are generally more informative than routine vesting-related sales; these transactions appear largely administrative (vesting → mandatory withholding sale + a gift) rather than discretionary investment decisions.